JC Viral Reactivation in a Pediatric Patient with Crohn's Disease

• Published in: International journal of immunopathology and pharmacology Vol. 23; no. 3; pp. 955 - 959
• Main Authors: Bellizzi, A., Barucca, V., Di Nardo, G., Fioriti, F., Iebba, V., Schippa, S., Conte, M.P., Checchi, M. Proietti, Colosimo, M.T., Cucchiara, S., Oliva, S., Chiarini, F., Pietropaolo, V.
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.07.2010
• Subjects: Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Biopsy; Child; Colon - pathology; Colon - virology; Colonoscopy; Crohn Disease - complications; Crohn Disease - diet therapy; Crohn Disease - drug therapy; DNA, Viral - genetics; Female; Humans; Intestines - pathology; Intestines - virology; JC Virus; Mesalamine - therapeutic use; Polyomavirus Infections - complications; Polyomavirus Infections - virology; Reverse Transcriptase Polymerase Chain Reaction; Crohn's disease; JCV reactivation; PML; 5-ASA
• ISSN: 0394-6320; 2058-7384
• DOI: 10.1177/039463201002300333

This is a report concerning human polyomavirus JC (JCV) reactivation in a pediatric patient with Crohn's disease (CD) during the treatment with 5-aminosalicylic acid (5-ASA), a non-steroidal anti-inflammatory drug (NSAID). We examined 9 bioptic samples from three different bowel districts (ileum, cecum, rectum) of this child. These samples were analyzed by Quantitative PCR (Q-PCR) to investigate the presence of JCV DNA. JCV DNA was detected in one rectum biopsy taken two months after 5-ASA treatment. Although our result must be validated in a larger group of subjects and with a longer follow-up period, it underlines the importance of JCV monitoring in CD patients.